Research Article
MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study
Table 2
MMP-2, MMP-9, and TIMP-4 concentrations in aspirin good responders and aspirin-HPR patients (according to different criteria).
| MMPs/TIMP-4 | LTA (Amax > 20%) | value
| LTA (Amax > 15%) | value
| MEA | value
| TXB2 > 3.1 ng/ml | value
| TXB2 > 5.8 ng/ml | value | (highest quartile) | (AspiTEST > 30 AU) | (highest quartile) | HPR + | HPR − | HPR + | HPR − | HPR + | HPR − | HPR + | HPR − | HPR + | HPR − | | | | | | | | | | |
| Plasma level | |
| MMP-2 (ng/ml) | 141.8 ± 21.2 | 155.1 ± 6.38 | 0.43 | 153.4 ± 11.3 | 154.8 ± 7.0 | 0.09 | 168.6 ± 15.1 | 149.9 ± 6.1 | 0.16 | 161.9 ± 12.4 | 149.7 ± 6.5 | 0.08 | 137.6 ± 7.9 | 160.6 ± 7.8 | 0.11 | MMP-9 (ng/ml) | 33.7 ± 6.8 | 47.0 ± 3.3 | 0.29 | 49.1 ± 5.4 | 45.9 ± 3.6 | 0.17 | 53.4 ± 6.6 | 43.6 ± 3.5 | 0.55 | 50.2 ± 4.8 | 41.4 ± 3.8 | 0.14 | 51.5 ± 7.0 | 42.6 ± 3.1 | 0.78 | TIMP-4 (pg/ml) | 1796.3 ± 354.1 | 1614.1 ± 94.4 | 0.33 | 1757.5 ± 222.8 | 1593.9 ± 99.7 | 0.44 | 1502.9 ± 136.8 | 1676.9 ± 114.1 | 0.17 | 1379.7 ± 106.7 | 1726.2 ± 127.8 | 0.87 | 1466.5 ± 140.0 | 1630.5 ± 112.2 | 0.06 |
| Supernatant of PRP after LTA induced by AA | |
| MMP-2 (ng/ml) | 141.1 ± 21.3 | 153.6 ± 6.0 | 0.70 | 153.3 ± 10.0 | 153.1 ± 6.7 | 0.06 | 166.4 ± 14.4 | 148.0 ± 5.9 | 0.90 | 157.1 ± 11.7 | 149.7 ± 6.3 | 0.15 | 134.2 ± 8.4 | 159.2 ± 7.3 | 0.13 | MMP-9 (ng/ml) | 33.0 ± 7.2 | 44.7 ± 2.67 | 0.12 | 48.3 ± 5.8 | 43.3 ± 2.8 | 0.34 | 43.3 ± 4.5 | 43.9 ± 3.1 | 0.14 | 43.9 ± 3.3 | 43.8 ± 3.5 | 0.78 | 42.8 ±.4.5 | 44.2 ± 3.0 | 0.62 | TIMP-4 (pg/ml) | 1762.6 ± 346.2 | 1568.9 ± 89.9 | 0.45 | 1694.0 ± 207.7 | 1553.0 ± 95.4 | 0.09 | 1465.3 ± 128.7 | 1629.6 ± 108.8 | 0.07 | 1364.5 ± 101.8 | 1662.4 ± 122.4 | 0.80 | 1440.9 ± 136.7 | 1579.4 ± 106.5 | 0.76 |
| Supernatant after 5 minutes of aspirin incubation and subsequent LTA induced by AA | |
| MMP-2 (ng/ml) | 135.6 ± 19.2 | 146.9 ± 5.9 | 0.22 | 148.1 ± 10.9 | 146.0 ± 6.5 | 0.08 | 157.7 ± 12.5 | 142.9 ± 6.2 | 0.08 | 151.6 ± 11.8 | 142.8 ± 6.4 | 0.08 | 129.2 ± 7.4 | 152.4 ± 7.2 | 0.34 | MMP-9 (ng/ml) | 35.8 ± 6.5 | 44.7 ± 2.8 | 0.53 | 51.7 ± 7.8 | 42.8 ± 2.8 | 0.41 | 40.6 ± 3.7 | 45.4 ± 3.4 | 0.36 | 45.1 ± 2.8 | 42.6 ± 3.5 | 0.78 | 44.2 ± 4.0 | 43.4 ± 3.0 | 0.08 | TIMP-4 (pg/ml) | 1748.0 ± 340.3 | 1548.4 ± 91.4 | 0.07 | 1669.4 ± 208.9 | 1533.7 ± 97.7 | 0.76 | 1459.3 ± 130.8 | 1604.1 ± 110.7 | 0.73 | 1360.7 ± 103.2 | 1632.7 ± 124.8 | 0.67 | 1439.7 ± 140.6 | 1553.7 ± 107.8 | 0.16 |
|
|
Notes. AA: arachidonic acid; AspiTEST: arachidonic acid-induced aggregation in MEA; LTA: light transmittance aggregometry; MEA: multielectrode aggregometry; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; TIMP-4: tissue inhibitor of matrix metalloproteinase-4; TXB2: thromboxane B2; HPR: high on treatment platelet reactivity; mean ± SEM.
|